Journal article icon

Journal article

6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.

Abstract:

Familial breast and ovarian cancers are often defective in homologous recombination (HR) due to mutations in the BRCA1 or BRCA2 genes. Cisplatin chemotherapy or poly(ADP-ribose) polymerase (PARP) inhibitors were tested for these tumors in clinical trials. In a screen for novel drugs that selectively kill BRCA2-defective cells, we identified 6-thioguanine (6TG), which induces DNA double-strand breaks (DSB) that are repaired by HR. Furthermore, we show that 6TG is as efficient as a PARP inhibit...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Journal:
Cancer research More from this journal
Volume:
70
Issue:
15
Pages:
6268-6276
Publication date:
2010-08-01
DOI:
EISSN:
1538-7445
ISSN:
0008-5472
Language:
English
Keywords:
Pubs id:
pubs:125300
UUID:
uuid:8c8e6603-2962-4129-87c4-9f461b1dc0a4
Local pid:
pubs:125300
Source identifiers:
125300
Deposit date:
2012-12-19

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP